STORM’s lead programme is the first RNA methyltransferase inhibitor to enter clinical development CAMBRIDGE, England, Aug. 9, 2023 /PRNewswire/ — STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.